Australian legal status , read first. In Australia, psilocybin (the principal compound studied in this context) remains a Schedule 9 Prohibited Substance under the Poisons Standard (the document that gives effect to the Therapeutic Goods Act 1989). Possession, use, or supply outside an authorised framework is a criminal offence under state and territory law. A narrow, tightly regulated exception has existed since 1 July 2023: Authorised Prescribers approved by the TGA may prescribe psilocybin (reclassified to Schedule 8 for this purpose only) and MDMA within an approved clinical context. This pathway does not constitute general legal access; it applies only to specific prescribers and specific patients under strict conditions. No over-the-counter or self-directed access exists.
What the model describes. In the research literature, psychedelic-assisted therapy refers to a structured protocol in which a psychedelic compound is administered on one or more occasions within a supervised clinical or research environment, bracketed by preparatory and integrative sessions with trained psychological support staff. Published trial designs , such as those described in peer-reviewed journals including The Lancet and JAMA Psychiatry , involve careful participant screening, monitored dosing sessions, and post-session follow-up. Doses reported in such studies are specific to those controlled research conditions and must not be interpreted as instructions for self-directed use, which remains illegal and carries serious safety risks including adverse psychological reactions, accidents, and drug interactions.
Regulatory and research context. Interest in this model grew substantially following rescheduling decisions in several jurisdictions and the granting of "Breakthrough Therapy" designation by the US Food and Drug Administration for certain investigational applications. In Australia, the TGA's 2023 rescheduling decision was accompanied by explicit guidance that the Authorised Prescriber pathway is not an endorsement of widespread clinical adoption and that evidence from large randomised controlled trials remains limited. The TGA and the Australian Drug Foundation both note that research findings to date; while generating scientific interest, come largely from small or methodologically constrained studies, and that effects attributed to these substances cannot be separated from the intensive therapeutic support provided alongside them.
Safety and legal warning. Psychedelic substances carry real risks including acute psychological distress, prolonged perceptual disturbance, and exacerbation of pre-existing mental health conditions. Outside the specific TGA-approved Authorised Prescriber framework, any possession or use of psilocybin or related compounds is illegal in Australia and may result in criminal prosecution. This entry is provided for educational and classificatory purposes only. It does not constitute medical advice, encourage use, or describe how to obtain any substance.
Sources: